MOUNTAIN VIEW, Calif., June 27, 2011 /PRNewswire/ —
ChemoCentryx, Inc. today announced that the Company’s novel CCR2
antagonist significantly improves kidney function and hyperglycemia
in experimental models. These data implicate CCR2-driven
processes in the pathology of type 2 diabetes and associated
complications such as diabetic nephropathy. Results were
highlighted in a poster presentation entitled “CCR2 Antagonism
Improves Renal Function and Hyperglycemia in Preclinical Models of
Type 2 Diabetes” at the 71st Scientific Session of the American
Diabetes Association held in San Diego. CCX140, the Company’s
lead novel, orally available CCR2 antagonist, successfully met its
primary endpoint of safety and tolerability in a Phase II clinical
trial in type 2 diabetes, while demonstrating clinical activity on
glycemic indices following only 28 days of treatment. CCX140
is currently poised to enter Phase II clinical development for the
treatment of diabetic nephropathy.
“In the United States there are more than 31 million patients
living with chronic kidney disease, 37% as a result of having
diabetes,” stated Thomas J. Schall, Ph.D., President and Chief
Executive Officer of ChemoCentryx. “Complicating matters
further is the fact that the current standard of care does not stop
or reverse progression and with the increasing number of patients
who progress to end-stage renal disease each year — there is a
clear demand for better treatment options. We believe these
data demonstrate compelling rationale to move forward CCX140, our
most advanced CCR2 antagonist, in a Phase II clinical trial for the
treatment of diabetic nephropathy.”
CCR2 inhibition was studied in two models of type 2 diabetes:
diet-induced obese mice and db/db mice. Treatment with
the CCR2 antagonist significantly improved multiple metabolic/renal
parameters in obese, diabetic mice, including hyperglycemia,
insulin sensitivity, serum adiponec
‘/>”/>
